Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00618267 · ClinicalTrials.gov registry record
ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 100
- Enrollment target
NCT00618267: Completed study, sponsored by Biogen.
NCT00618267 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00618267 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to see if we can find a new way to test how certain Multiple Sclerosis (MS) medications work in the body and to better understand how the medicines change certain substances (cells) found in the immune (protective) system. Blood test will be drawn by doing the following: * Use a new method called the "Immuknow®" Test to see if this method will help to better understand how MS medicines work. * Measure certain levels of immune cells in a new way, to see if it this will help to understand the body's response to MS medicines. These methods will test those with MS who are not taking any MS medications, to help us compare the results. About 100 subjects will be enrolled in this study at the Partners Multiple Sclerosis Center at Brigham and Women's Hospital. Biogen Idec, Inc. of Cambridge, MA, is paying for this study to be done.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-12 |
What the finished NCT00618267 record still lists
NCT00618267 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00618267 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00618267 about?
NCT00618267 is a clinical study titled "ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.". The purpose of this study is to see if we can find a new way to test how certain Multiple Sclerosis (MS) medications work in the body and to better understand how the medicines change certain substances (cells) found in the immune (protective) system. Blood test will be drawn by doing the following...
What is the current status of trial NCT00618267?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2008-03. Estimated completion is 2008-12.
Who is sponsoring clinical trial NCT00618267?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia